Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 3/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 7/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.33 |
| ▸ | CDK1 | P06493 | 2/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29882790 | 0.80 | ADORA1 (0.38) | ADORA2AEGFRHSP90AA1 | |
| SCHEMBL29936384 | 0.76 | HASPIN (0.33) | EGFRHSP90AA1 | |
| SCHEMBL30112955 | 0.74 | ADORA2A (0.43) | ADORA2ADCPSDHFR | |
| SCHEMBL30575925 | 0.74 | EGFR (0.39) | ADORA2AEGFRHSP90AA1CDK1CDK2 | |
| SCHEMBL17362696 | 0.74 | EGFR (0.39) | ADORA2AEGFRHSP90AA1CDK1CDK2 | |
| SCHEMBL30575908 | 0.73 | MAP4K4 (0.34) | EGFRPIK3CG | |
| SCHEMBL9014935 | 0.72 | ADORA2A (0.66) | ADORA2ADHFRPIK3CG | |
| SCHEMBL10375776 | 0.71 | DHFR (0.42) | ADORA2ADCPSDHFRPIK3CG | |
| SCHEMBL6036330 | 0.70 | CDK1 (0.44) | ADORA2AEGFRHSP90AA1CDK1CCNB1 | |
| SCHEMBL1821262 | 0.70 | EGFR (0.44) | EGFRHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023078241-A1 | AROMATIC AMINE DERIVATIVES AND PREPARATION METHOD AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2023-05-11 | — | — | WO | disclosed |
| US-20080090847-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF AS D-ALANYL-D-ALANINE LIGASE INHIBITORS | PLIVA D.D. (HR) | 2008-04-17 | — | — | US | disclosed |
| US-7345048-B2 | Heterocyclic compounds and uses thereof as D-alanyl-D-alanine ligase inhibitors | PLIVA D.D. (HR) | 2008-03-18 | — | — | US | disclosed |
| EP-1432713-A4 | FUSED PYRIMIDINE DHFR INHIBITORS AS ANTIBACTERIALS | ESSENTIAL THERAPEUTICS INC (US) | 2005-05-11 | — | — | EP | disclosed |
| EP-1411949-A4 | 8/17 HETEROCYCLIC COMPOUNDS AND USES THEREOF AS D-ALANYL-D-ALANINE LIGASE INHIBITORS | ESSENTIAL THERAPEUTICS INC (US) | 2004-11-24 | — | — | EP | disclosed |
| EP-1432713-A2 | FUSED PYRIMIDINE DHFR INHIBITORS AS ANTIBACTERIALS | Essential Therapeutics, Inc. (US) | 2004-06-30 | — | — | EP | disclosed |
| EP-1411949-A2 | 8/17 HETEROCYCLIC COMPOUNDS AND USES THEREOF AS D-ALANYL-D-ALANINE LIGASE INHIBITORS | Essential Therapeutics, Inc. (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20030181470-A1 | Heterocyclic compounds and uses thereof as D-alanyl-D-alanine ligase inhibitors | ESSENTIAL THERAPEUTICS, INC. | 2003-09-25 | — | — | US | disclosed |
| US-20030176436-A1 | Novel heterocyclic compounds as selective bacterial DHFR inhibitors and their uses thereof | ALA PAUL J (DE) | 2003-09-18 | — | — | US | disclosed |
| WO-2003002064-A2 | FUSED PYRIMIDINE DHFR INHIBITORS AS ANTIBACTERIALS | ESSENTIAL THERAPEUTICS, INC. (US) | 2003-01-09 | — | — | WO | disclosed |
| WO-2003001887-A2 | FUSED PYRIMIDINES AS D-ALANYL-D-ALANINE LIGASE INHIBITORS | ESSENTIAL THERAPEUTICS, INC. (US) | 2003-01-09 | — | — | WO | disclosed |
| EP-0257488-B1 | Novel diaminopyrimido[4,5-d]pyrimidine glycoside and glycotide and process | WARNER-LAMBERT COMPANY (US) | 1992-04-29 | — | — | EP | disclosed |
| US-4801698-A | Process for preparing diaminopyrimido(4,5-d)pyrimidine glycoside and glycotide | WARNER-LAMBERT COMPANY (US) | 1989-01-31 | — | — | US | disclosed |
| EP-0257488-A2 | Novel diaminopyrimido[4,5-d]pyrimidine glycoside and glycotide and process | WARNER-LAMBERT COMPANY (US) | 1988-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181470-A1 | Heterocyclic compounds and uses thereof as D-alanyl-D-alanine ligase inhibitors | AAAS, ALAD, NAALAD2 | ADORA2A 3237/4885EGFR 3413/4885HSP90AA1 3522/4885 |
| US-20030176436-A1 | Novel heterocyclic compounds as selective bacterial DHFR inhibitors and their uses thereof | DHFR, DHODH, DPYD | ADORA2A 3158/4885EGFR 4228/4885HSP90AA1 1168/4885 |
| US-20080090847-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF AS D-ALANYL-D-ALANINE LIGASE INHIBITORS | AAAS, ALAD, NAALAD2 | ADORA2A 3237/4885EGFR 3413/4885HSP90AA1 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.